2.The Thrombectomy Dilemma in Stroke Patients With Active Cancer: To Treat or Not to Treat?
Yohanna KUSUMA ; Mikiya BEPPU ; Beom Joon KIM ; Sung-Chun TANG ; Mikito HAYAKAWA ; Hiroshi YAMAGAMI ; Hiroyuki KAWANO ; Teruyuki HIRANO ; Shinichi YOSHIMURA ; Hamidon BASRI ; Richard LI ; Huy Thang NGUYEN ; Deidre Anne De SILVA ; Keun-Sik HONG ; Jiann-Shing JENG ; Than G. PHAN ; Henry MA ; Bernard YAN ;
Journal of Stroke 2026;28(2):218-227
Endovascular thrombectomy for acute large-vessel occlusion in patients with active cancer remains a difficult clinical decision. Multiple cohort studies and meta-analyses indicate that, when standard imaging and clinical criteria are applied, reperfusion success is high and symptomatic intracranial hemorrhage is broadly comparable with non-cancer populations, arguing against categorical exclusion. At the same time, registries show lower 90-day functional independence and higher 90-day mortality in active-cancer cohorts—effects likely driven by malignancy-related systemic factors and pre-existing functional compromise rather than procedural harm. This narrative review synthesizes efficacy and safety signals, highlights decision-grade outcomes that are seldom reported—early neurological change, performance status around 90 days, and whether systemic anticancer therapy is started or resumed. It sets out a clinical–ethical–economic framework to support selection, consent, and aftercare, including a pragmatic pathway for under-resourced settings based on non-contrast computed tomography (CT) or single-phase CT angiography where advanced perfusion imaging or magnetic resonance imaging are unavailable. We outline an Asia–Pacific collaborative program designed to identify subgroups that may benefit from reperfusion and initiation of active cancer care.
3.Thrombectomy With Bridging Thrombolytic May Benefit Asian Patients More Than Non-Asian Patients: Insights From DIRECT-SAFE Sub-Analysis
James L. BARKER ; Oshi SWARUP ; Yohanna KUSUMA ; Leonid CHURILOV ; Geoffrey DONNAN ; Stephen M. DAVIS ; Peter J. MITCHELL ; Bernard YAN
Journal of Stroke 2025;27(1):118-121
4.Robotic Stroke Thrombectomy: A Feasibility and Efficacy Study in Flow Models
Cameron J. WILLIAMS ; Hal RICE ; Bernard YAN ; Laetitia de VILLIERS ; Vinicius Carraro do NASCIMENTO ; Peter J. MITCHELL ; Nathan W. MANNING ; Leonid CHURILOV ; Mark W. PARSONS ; Stephen M. DAVIS ; Geoffrey A. DONNAN
Journal of Stroke 2025;27(2):266-269
5.Thrombectomy With Bridging Thrombolytic May Benefit Asian Patients More Than Non-Asian Patients: Insights From DIRECT-SAFE Sub-Analysis
James L. BARKER ; Oshi SWARUP ; Yohanna KUSUMA ; Leonid CHURILOV ; Geoffrey DONNAN ; Stephen M. DAVIS ; Peter J. MITCHELL ; Bernard YAN
Journal of Stroke 2025;27(1):118-121
6.Robotic Stroke Thrombectomy: A Feasibility and Efficacy Study in Flow Models
Cameron J. WILLIAMS ; Hal RICE ; Bernard YAN ; Laetitia de VILLIERS ; Vinicius Carraro do NASCIMENTO ; Peter J. MITCHELL ; Nathan W. MANNING ; Leonid CHURILOV ; Mark W. PARSONS ; Stephen M. DAVIS ; Geoffrey A. DONNAN
Journal of Stroke 2025;27(2):266-269
7.Thrombectomy With Bridging Thrombolytic May Benefit Asian Patients More Than Non-Asian Patients: Insights From DIRECT-SAFE Sub-Analysis
James L. BARKER ; Oshi SWARUP ; Yohanna KUSUMA ; Leonid CHURILOV ; Geoffrey DONNAN ; Stephen M. DAVIS ; Peter J. MITCHELL ; Bernard YAN
Journal of Stroke 2025;27(1):118-121
8.Robotic Stroke Thrombectomy: A Feasibility and Efficacy Study in Flow Models
Cameron J. WILLIAMS ; Hal RICE ; Bernard YAN ; Laetitia de VILLIERS ; Vinicius Carraro do NASCIMENTO ; Peter J. MITCHELL ; Nathan W. MANNING ; Leonid CHURILOV ; Mark W. PARSONS ; Stephen M. DAVIS ; Geoffrey A. DONNAN
Journal of Stroke 2025;27(2):266-269
9.Effect of the Coronavirus Disease 2019 Pandemic on the Quality of Stroke Care in Stroke Units and Alternative Wards: A National Comparative Analysis
Dominique A. CADILHAC ; Joosup KIM ; Geoffrey CLOUD ; Craig S. ANDERSON ; Emma K. TOD ; Sibilah J. BREEN ; Steven FAUX ; Timothy KLEINIG ; Helen CASTLEY ; Richard I. LINDLEY ; Sandy MIDDLETON ; Bernard YAN ; Kelvin HILL ; Brett JONES ; Darshan SHAH ; Katherine JAQUES ; Benjamin CLISSOLD ; Bruce CAMPBELL ; Natasha A. LANNIN ;
Journal of Stroke 2022;24(1):79-87
Background:
and Purpose Changes to hospital systems were implemented from March 2020 in Australia in response to the coronavirus disease 2019 pandemic, including decreased resources allocated to stroke units. We investigate changes in the quality of acute care for patients with stroke or transient ischemic attack during the pandemic according to patients’ treatment setting (stroke unit or alternate ward).
Methods:
We conducted a retrospective cohort study of patients admitted with stroke or transient ischemic attack between January 2019 and June 2020 in the Australian Stroke Clinical Registry (AuSCR). The AuSCR monitors patients’ treatment setting, provision of allied health and nursing interventions, prescription of secondary prevention medications, and discharge destination. Weekly trends in the quality of care before and during the pandemic period were assessed using interrupted time series analyses.
Results:
In total, 18,662 patients in 2019 and 8,850 patients in 2020 were included. Overall, 75% were treated in stroke units. Before the pandemic, treatment in a stroke unit was superior to alternate wards for the provision of all evidence-based therapies assessed. During the pandemic period, the proportion of patients receiving a swallow screen or assessment, being discharged to rehabilitation, and being prescribed secondary prevention medications decreased by 0.58% to 1.08% per week in patients treated in other ward settings relative to patients treated in stroke units. This change represented a 9% to 17% increase in the care gap between these treatment settings during the period of the pandemic that was evaluated (16 weeks).
Conclusions
During the first 6 months of the pandemic, widening care disparities between stroke units and alternate wards have occurred.
10.DIRECT-SAFE: A Randomized Controlled Trial of DIRECT Endovascular Clot Retrieval versus Standard Bridging Therapy
Peter J. MITCHELL ; Bernard YAN ; Leonid CHURILOV ; Richard J. DOWLING ; Steven BUSH ; Thang NGUYEN ; Bruce C.V. CAMPBELL ; Geoffrey A. DONNAN ; Zhongrong MIAO ; Stephen M. DAVIS ;
Journal of Stroke 2022;24(1):57-64
Background:
and Purpose The benefit regarding co-treatment with intravenous (IV) thrombolysis before mechanical thrombectomy in acute ischemic stroke with large vessel occlusion remains unclear. To test the hypothesis that clinical outcome of ischemic stroke patients with intracranial internal carotid artery, middle cerebral artery or basilar artery occlusion treated with direct endovascular thrombectomy within 4.5 hours will be non-inferior compared with that of standard bridging IV thrombolysis followed by endovascular thrombectomy.
Methods:
To randomize 780 patients 1:1 to direct thrombectomy or bridging IV thrombolysis with thrombectomy. An international-multicenter prospective randomized open label blinded endpoint trial (PROBE) (ClincalTrials.gov identifier: NCT03494920).
Results:
Primary endpoint is functional independence defined as modified Rankin Scale (mRS) 0–2 or return to baseline at 90 days. Secondary end points include ordinal mRS analysis, good angiographic reperfusion (modified Thrombolysis in Cerebral Infarction score [mTICI] 2b–3), safety endpoints include symptomatic intracerebral hemorrhage and death.
Conclusions
DIRECT-SAFE will provide unique information regarding the impact of direct thrombectomy in patients with large vessel occlusion, including patients with basilar artery occlusion, with comparison across different ethnic groups.

Result Analysis
Print
Save
E-mail